Bioventus (BVS) Payables (2020 - 2026)

Bioventus (BVS) has 7 years of Payables data on file, last reported at $24.0 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 25.28% year-over-year to $24.0 million; the trailing twelve-month figure through Mar 2026 stood at $24.0 million (up 25.28% YoY), and the FY2025 full-year result was $10.9 million, down 53.87% from the prior year.
• Payables for Q1 2026 stood at $24.0 million, up from $10.9 million in the prior quarter.
• Across five years, Payables topped out at $41.4 million in Q3 2023 and bottomed at $10.9 million in Q4 2025.
• The 5-year median for Payables is $23.7 million (2024), against an average of $24.0 million.
• The widest annual swing landed in 2022, when Payables surged 160.45%; it then slumped 53.87% in 2025.
• A 5-year view of Payables shows it stood at $36.7 million in 2022, then sank by 37.22% to $23.0 million in 2023, then climbed by 2.83% to $23.7 million in 2024, then plunged by 53.87% to $10.9 million in 2025, then soared by 120.08% to $24.0 million in 2026.
• The last three Payables figures came in at $24.0 million (Q1 2026), $10.9 million (Q4 2025), and $26.6 million (Q3 2025), per Business Quant data.

Peer Comparison